• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Hookipa Pharma Inc (NQ: HOOK )

    3.760 +0.070 (+1.90%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Hookipa Pharma Inc

    < Previous 1 2 3 4 5 6 7 8 9 Next >
    HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024
    Society of Immunotherapy of Cancer (SITC) poster to be presented by collaborator from Memorial Sloan Kettering Cancer Center, Dr. Alan Ho, on November 9, 2024 
    From HOOKIPA Pharma Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga
    HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer
    From HOOKIPA Pharma Inc.
    Via GlobeNewswire
    Why HOOKIPA Pharma (HOOK) Stock Is Volatile Today
    HOOKIPA Pharma shares are trading lower by 10.9% during Monday's session. The company announced a 1-for-10 reverse stock split. 
    Via Benzinga
    Deep Dive Into HOOKIPA Pharma Stock: Analyst Perspectives (4 Ratings)
    Via Benzinga
    Breaking Down HOOKIPA Pharma: 4 Analysts Share Their Views
    Via Benzinga
    HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset
    Preclinical proof-of-concept package to be presented at Industry Summit on RAS being held September 24-26, 2024 
    From HOOKIPA Pharma Inc.
    Via GlobeNewswire
    Kaskela Law LLC Announces Shareholder Investigation of HOOKIPA Pharma Inc. (NASDAQ: HOOK) and Encourages Investors to Contact the Firm
    From Kaskela Law LLC
    Via Business Wire
    HOOKIPA Pharma Announces Board of Directors Changes
    From HOOKIPA Pharma Inc.
    Via GlobeNewswire
    HOOK Stock Earnings: HOOKIPA Pharma Misses EPS, Misses Revenue for Q2 2024
    HOOK stock results show that HOOKIPA Pharma missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
    Via InvestorPlace
    HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights
    From HOOKIPA Pharma Inc.
    Via GlobeNewswire
    HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200
    From HOOKIPA Pharma Inc.
    Via GlobeNewswire
    HOOKIPA Pharma Announces Effective Date of 1-for-10 Reverse Stock Split
    From HOOKIPA Pharma Inc.
    Via GlobeNewswire
    HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV
    From HOOKIPA Pharma Inc.
    Via GlobeNewswire
    Keurig Dr Pepper To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday
    Via Benzinga
    HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting
    From HOOKIPA Pharma Inc.
    Via GlobeNewswire
    HOOKIPA Pharma to Host Investor Call on HB-200 Data Presented at American Society of Clinical Oncology 2024 Annual Meeting
    From HOOKIPA Pharma Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    HOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual Meeting
    From HOOKIPA Pharma Inc.
    Via GlobeNewswire
    Penny Stock Sleepers: 7 Under-the-Radar Gems Ready to Launch
    Penny stocks to buy understandably offers many enticing attributes, not least of which is the potential for tremendous returns. 
    Via InvestorPlace
    HOOK Stock Earnings: HOOKIPA Pharma Beats EPS, Beats Revenue for Q1 2024
    HOOK stock results show that HOOKIPA Pharma beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
    Via InvestorPlace
    HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
    From HOOKIPA Pharma Inc.
    Via GlobeNewswire
    Stocks Creating Buzz Look Now: VTAK, AMST, HOOK, MULN, KAVL
    Via AB Newswire
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab
    From HOOKIPA Pharma Inc.
    Via GlobeNewswire
    Why Is Penny Stock HOOKIPA Pharma Trading Higher On Wednesday?
    HOOKIPA Pharma secures FDA clearance for its innovative HB-700 therapeutic vaccine targeting KRAS-mutated cancers. Learn about its broad impact on lung, colorectal, and pancreatic cancers, achieving... 
    Via Benzinga
    Exposures Product Safety
    HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers
    From HOOKIPA Pharma Inc.
    Via GlobeNewswire
    HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
    From HOOKIPA Pharma Inc.
    Via GlobeNewswire
    Roche's Lymphoma Drug With Chemo Extends Survival In Pretreated Patients
    Roche study results show prolonged survival in R/R diffuse large B-cell lymphoma patients treated with Columvi (glofitamab) + GemOx vs. Rituxan + GemOx. 
    Via Benzinga
    HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration
    From HOOKIPA Pharma Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.